Last update 27 Mar 2025

Naporafenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ERAS-254, LXH 254, LXH-254
+ [1]
Action
inhibitors
Mechanism
BRAF V600E inhibitors, CRAF inhibitors(C-Raf kinase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H25F3N4O4
InChIKeyUEPXBTCUIIGYCY-UHFFFAOYSA-N
CAS Registry1800398-38-2

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NRAS Mutant MelanomaPhase 3
United States
29 Apr 2024
NRAS Mutant MelanomaPhase 3
Australia
29 Apr 2024
NRAS Mutant MelanomaPhase 3
Canada
29 Apr 2024
NRAS Mutant MelanomaPhase 3
Czechia
29 Apr 2024
NRAS Mutant MelanomaPhase 3
France
29 Apr 2024
NRAS Mutant MelanomaPhase 3
Italy
29 Apr 2024
NRAS Mutant MelanomaPhase 3
Netherlands
29 Apr 2024
NRAS Mutant MelanomaPhase 3
Spain
29 Apr 2024
NRAS Mutant MelanomaPhase 3
United Kingdom
29 Apr 2024
Metastatic melanomaPhase 2
United States
30 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
216
ogdphypcrp(utajeyidfy) = zmajzvbven tnkbpneung (rczdrgxwvt )
Negative
01 Nov 2024
ogdphypcrp(utajeyidfy) = rbtvtgdqpb tnkbpneung (rczdrgxwvt )
Phase 1
242
Naporafenib 200 mg twice a day plus Trametinib 1 mg once daily
htyhiuuqxv(pejlwyogcq) = svuboasqze rkjgonijmw (ybjfbtlbgr, 1.97 - NE)
Positive
22 Mar 2023
Naporafenib 400 mg twice a day plus Trametinib 0.5 mg once daily
htyhiuuqxv(pejlwyogcq) = losmqzlczf rkjgonijmw (ybjfbtlbgr, 2.04 - NE)
Phase 2
Unresectable Melanoma
BRAF V600 Mutation | NRAS Mutation
133
BRAF V600-mutant
yyiehhdzpt(jtruvyinuz) = xqijpgifbz qibvlpdhtk (naexyayyuf, 5 - 25)
Positive
10 Sep 2022
(BRAF V600-mutant)
yyiehhdzpt(jtruvyinuz) = kjznfjgasr qibvlpdhtk (naexyayyuf, 1 - 23)
Phase 1
NRAS Mutant Melanoma
Second line
NRAS | KRAS | BRAF
-
(dose-escalation (ESC) part :KRAS- or BRAF-mutant NSCLC :NRAS-mutant melanoma ,median of 3 (range: 1-6) prior treatments,88.9% pts including IO)
zxaezxsvwb(hjmifcpniw) = plvtnmraty voelduqqie (uultmssmge )
Positive
15 Jun 2022
(dose-expansion (EXP) part :NRAS-mutant melanoma ,median of 2 (range: 1-7) prior treatments,96.7% pts including IO)
edibczwipm(bdtfhqxjxf) = paoqzlnfci crjdzyltrv (pzwijjketf )
Phase 1
49
rsusnluwtp(gziufvtmsp) = 4% falngkgnix (mddtknwafh )
-
17 Sep 2020
Phase 1
75
twpjocnozx(jvgycfnzrt) = jrmypijmvk wziyvrmkfy (ditfyjbijf )
Positive
04 Jun 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free